Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Docetaxel Addition in Metastatic Castrate-Sensitive Prostate Cancer (ASPIRE)

NCT06931340 is registered in ClinicalTrials.gov with Alliance for Clinical Trials in Oncology as lead sponsor.

NCT NCT06931340
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06931340 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Docetaxel Addition in Metastatic Castrate-Sensitive Prostate Cancer (ASPIRE)
Lead sponsor
Alliance for Clinical Trials in Oncology
Phase
Phase 3
Overall status
Recruiting
Start date
December 1, 2025
Completion date
May 8, 2039
Enrollment
1,260 (estimated)
Sites
213

Conditions

As the registry lists them; a condition with its own page is linked.

castration-sensitive prostate carcinoma, metastatic prostate adenocarcinoma, stage ivb prostate cancer ajcc v8